<b>beta</b><sub>3</sub>-Adrenergic receptor polymorphism and metabolic syndrome in postmenopausal women

Dunajska, Katarzyna; Lwow, Felicja; Milewicz, Andrzej; Jędrzejuk, Diana; Łaczmański, Łukasz; Belowska-Bień, Kinga; Urban, Joanna; Szuba, Andrzej

doi:10.1080/09513590801921686

Cited by 17 publications

(15 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, adiponectin concentrations increased markedly in patients who took rosiglitazone for 12 weeks, and a lesser increase of adiponectin was observed in patients with the Trp64Arg genotype, possibly due, in our opinion, to lower PPAR expression in this group. Although without statistical significance, a recent study found the Trp64Arg variant could be associated with lipid profile disorders in postmenopausal women [31]. In our study, the Trp64Arg variant was also associated with a greater decrease of TG and less decrease of LDLcholesterol, but detailed explanation of this phenomenon must await study of larger samples.…”

Section: Discussioncontrasting

confidence: 47%

Effects of UCP2 –866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes

Yang

Huang

et al. 2009

Brit J Clinical Pharma

View full text Add to dashboard Cite

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Rosiglitazone is one of the thiazolidinedione medicines that is widely used in patients with Type 2 diabetes (T2DM); it acts by activation of peroxisome proliferatoractivated receptor-g. • There are no reports on the influence of genetic variations of UCP2 and ADRB3 on rosiglitazone response in Chinese T2DM patients.• The current study was designed to evaluate the relationship between the genetic polymorphisms of UCP2 -866G/A and ADRB3 Trp64Arg with susceptibility to T2DM development and the therapeutic efficacy of multiple-dose rosiglitazone in Chinese patients with T2DM. WHAT THIS STUDY ADDS• The genetic polymorphisms of UCP2 -866G/A and ADRB3 Trp64Arg are associated with the therapeutic efficacy of multipledose rosiglitazone in Chinese T2DM patients. AIMSThe aim of this study was to explore the impact of UCP2 and ADRB3 genetic polymorphisms on the therapeutic efficacy of rosiglitazone in Chinese Type 2 diabetes (T2DM) patients. ) for 12 weeks. Serum fasting plasma glucose, postprandial plasma glucose, glycated haemoglobin (HbA1c), fasting serum insulin, postprandial serum insulin (PINS), triglycerol (TG), cholesterol, homeostasis model assessment for insulin resistance, leptin and adiponectin in all T2DM patients were determined before and after rosiglitazone treatment. METHODS RESULTSThere were no differences in allele frequency of either ADRB3 Trp64Arg or UCP2 -866 G/A between T2DM patients and control subjects. The A allele carriers of UCP2 in the T2DM patients had significantly lower PINS (61.5 Ϯ 34.3 vs. 41.6 Ϯ 28.7 mU l -1 , P < 0.01) (37.57, 59.16 vs. 34.82, 49.39) and low-density lipoprotein (LDL)-cholesterol compared with GG genotypes (3.4 Ϯ 1.1 vs. 2.7 Ϯ 1.1 mmol l -1 , P < 0.05) (2.64, 3.52 vs. 2.66, 3.15). After rosiglitazone treatment for 12 consecutive weeks, we found that A allele carriers of UCP2 in the T2DM patients had smaller attenuated PINS (-3.82 Ϯ 13.2 vs. -42.1 Ϯ 30.7 mU l -1 , P < 0.01) (9.45, 51.31 vs. 0.48, 11.88) and greater attenuated HbA1c (-1.85 Ϯ 1.62 vs. -0.61 Ϯ 0.80, P < 0.05) (0.14, 1.37 vs. 1.10, 2.38) compared with GG genotypes, and ADRB3 Trp64Arg had greater attenuated serum TG (-3

show abstract

Section: Discussioncontrasting

confidence: 47%

Effects of UCP2 –866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes

Yang

Huang

et al. 2009

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Involvement of a gene in multiple MetS pathways did not guarantee an association for SNPs in this gene with MetS. The evidence for an association with MetS was weak for SNPs in the ADRB2 (20,21,46,86) and ADRB3 (21,46,87–89) gene, genes involved in glucose metabolism, lipid metabolism and blood pressure regulation (86), SNPs in the LEPR gene (54,90,91), which is involved in body weight regulation, fatty acid oxidation and glucose metabolism (92); SNPs in the PPARD gene (21,93,94), which regulates both glucose and energy metabolism (94); and SNPs in the PPARGC1A gene (11,21,46,95), which is involved in lipid and glucose metabolism (95). However, for the Ala54Thr (rs1799883) SNP (18,35,48,96–98) in the FABP2 gene, which is involved in both fatty acid and glucose metabolism (96,97), some evidence for an association with MetS exists.…”

Section: Resultsmentioning

confidence: 99%

Genetic variants and the metabolic syndrome: a systematic review

et al. 2011

View full text Add to dashboard Cite

SummarySeveral candidate gene studies on the metabolic syndrome (MetS) have been conducted. However, for most single nucleotide polymorphisms (SNPs) no systematic review on their association with MetS exists. A systematic electronic literature search was conducted until the 2nd of June 2010, using HuGE Navigator. English language articles were selected. Only genes of which at least one SNP-MetS association was studied in an accumulative total population Ն4000 subjects were included. Meta-analyses were conducted on SNPs with three or more studies available in a generally healthy population. In total 88 studies on 25 genes were reviewed. Additionally, for nine SNPs in seven genes (GNB3, PPARG, TCF7L2, APOA5, APOC3, APOE, CETP) a meta-analysis was conducted. The minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS. After having systematically reviewed the most studied SNP-MetS associations, we found evidence for an association with the MetS for eight SNPs, mostly located in genes involved in lipid metabolism.

show abstract

“…10 Simultaneously, lower concentrations of HDL lipoprotein as well as higher concentrations of C-reactive protein are seen in individuals who express the Trp64/Arg64 genotype. 7,11 Individuals with the Trp64Arg genotype are also more likely to develop hyperuricaemia. 12 Similarly, obese individuals who express the Trp64Arg genotype are 2.63 times more likely to develop colon carcinoma in comparison with patients who express the Trp64 genotype.…”

Section: Kathryn Wood and Charles Van Heyningenmentioning

confidence: 99%

Trp64Arg polymorphisms of the Beta3-adrenergic receptor gene and systemic disorders of metabolism: a close association

Kapoor

2009

Ann Clin Biochem

View full text Add to dashboard Cite

beta₃-Adrenergic receptor polymorphism and metabolic syndrome in postmenopausal women

Abstract: Trp64Arg polymorphism of the beta(3)-adrenergic receptor gene is not related to metabolic syndrome in postmenopausal Polish women; however, it seems to be associated with decreased HDL-C levels.

Cited by 17 publications

References 37 publications

Effects of UCP2 –866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes

Effects of UCP2 –866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes

Genetic variants and the metabolic syndrome: a systematic review

Trp64Arg polymorphisms of the Beta3-adrenergic receptor gene and systemic disorders of metabolism: a close association

Contact Info

Product

Resources

About

beta3-Adrenergic receptor polymorphism and metabolic syndrome in postmenopausal women

Abstract: Trp64Arg polymorphism of the beta(3)-adrenergic receptor gene is not related to metabolic syndrome in postmenopausal Polish women; however, it seems to be associated with decreased HDL-C levels.

Cited by 17 publications

References 37 publications

Effects of UCP2 –866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes

Effects of UCP2 –866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes

Genetic variants and the metabolic syndrome: a systematic review

Trp64Arg polymorphisms of the Beta3-adrenergic receptor gene and systemic disorders of metabolism: a close association

Contact Info

Product

Resources

About

beta₃-Adrenergic receptor polymorphism and metabolic syndrome in postmenopausal women